Royalty Pharma plc (OQ:RPRX)

Sep 06, 2022 04:15 pm ET
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 17th Annual BioPharma Conference on Thursday, September 8 at 11:20 a.m. ETMorgan...
Aug 04, 2022 07:00 am ET
Royalty Pharma Reports Second Quarter 2022 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “We continue to make excellent progress against our...
Jul 15, 2022 08:15 am ET
Royalty Pharma Declares Third Quarter 2022 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the...
Jul 14, 2022 08:30 am ET
Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at...
Jul 13, 2022 04:25 pm ET
Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and...
Jul 13, 2022 04:05 pm ET
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights to TRELEGY ELLIPTA Outer Year Royalties1Royalty Pharma to Invest up to $40 Million to Advance Development of Ampreloxetine in Multiple System Atrophy (MSA) in Exchange for Unsecured Low Single-Digit Royalties Theravance Biopharma to Hold a Conference Call Today at 5 pm ET / 2 pm PT / 10 pm ISTDUBLIN, July 13, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the
Jun 30, 2022 07:30 am ET
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in...
Jun 30, 2022 07:15 am ET
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
Strengthens balance sheet with significant non-dilutive, low-cost capitalExpands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business developmentPropelled by global launches of AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), and shared confidence in the important growth opportunity in systemic mastocytosisBlueprint Medicines will receive $575 million in total cash funded at closeCAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced strategic financing
Jun 08, 2022 08:30 am ET
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at...
May 23, 2022 08:30 am ET
Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at...
May 17, 2022 07:00 am ET
Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders
Royalty Pharma plc (Nasdaq: RPRX) will host its inaugural Investor Day in New York City today. Royalty Pharma’s management team will provide an update on the company’s capital deployment opportunities and long-term outlook and the prospects for...
May 05, 2022 07:00 am ET
Royalty Pharma Reports First Quarter 2022 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “We are delighted to start the year with a strong...
Apr 18, 2022 08:00 am ET
Royalty Pharma Declares Second Quarter 2022 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the...
Apr 14, 2022 10:55 am ET
Thinking about buying stock in Kaleido Biosciences, Royalty Pharma, PG&E Corp, Bitnile, or Delta Air Lines?
NEW YORK, April 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KLDO, RPRX, PCG, NILE, and DAL.
Apr 13, 2022 08:00 am ET
Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00...
Mar 29, 2022 08:00 am ET
Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment
NEW YORK and RYE BROOK, N.Y., March 29, 2022 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) today announced a charitable commitment totaling $7.5 million to The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer. Through this five-year alliance, Royalty Pharma will support initiatives focused on reducing healthcare disparities in blood cancer care and treatment. Royalty Pharma is a founding donor of the LLS IMPACT grant program (Influential Medicine Providing Access to Clinical Trials) which awards funding to major cancer research and treatment center
Mar 03, 2022 08:30 am ET
Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference
Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events”...
Feb 16, 2022 08:15 am ET
Royalty Pharma Announces Inaugural Investor Day
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m. ET. Royalty Pharma senior executives will present on the outlook for royalty funding in...
Feb 15, 2022 07:00 am ET
Royalty Pharma Reports Q4 and Full Year 2021 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts(1) (a non-GAAP financial measure) guidance. “Royalty Pharma had an...
Jan 20, 2022 07:45 am ET
Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and...
Jan 10, 2022 07:00 am ET
Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference
2021 Net cash provided by operating activities (GAAP) expected to be in the range of $2,010 to $2,030 million; 2021 Adjusted Cash Receipts (non-GAAP) expected to be at high end of guidance range of $2,110 to $2,130 million20 therapies added to...
Jan 07, 2022 08:07 am ET
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv mecarbil and the further...
Jan 07, 2022 07:30 am ET
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv mecarbil and the further...
Jan 06, 2022 08:30 am ET
Royalty Pharma Announces 12% Dividend Increase
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company’s quarterly dividend over the previous...
Jan 05, 2022 04:15 pm ET
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at...
Nov 29, 2021 04:15 pm ET
Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET. The webcast will be accessible from Royalty...
Nov 22, 2021 07:10 am ET
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals
Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing. The...
Nov 16, 2021 10:00 am ET
Thinking about buying stock in Porch Group, Royalty Pharma, Lucid Group, 360 DigiTech, or Hyzon Motors?
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRCH, RPRX, LCID, QFIN, and HYZN.
Nov 10, 2021 07:00 am ET
Royalty Pharma Reports Third Quarter 2021 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “We are delighted to report another quarter of...
Oct 18, 2021 09:00 am ET
Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous...
Oct 15, 2021 09:00 am ET
Royalty Pharma Declares Fourth-Quarter 2021 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on December 15, 2021, to shareholders of record at the...
Sep 03, 2021 09:00 am ET
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m....
Aug 11, 2021 07:00 am ET
Royalty Pharma Reports Second Quarter 2021 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure)....
Jul 19, 2021 09:00 am ET
Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous...
Jul 16, 2021 09:00 am ET
Royalty Pharma Declares Third-Quarter 2021 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share. The dividend will be paid on September 15, 2021, to shareholders of record at the...
Jul 15, 2021 04:54 pm ET
Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond
Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 2.15% Senior Notes due 2031 (the “Social Bonds”);...
Jun 07, 2021 09:00 am ET
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June: Goldman Sachs Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. EDTBank of America...
Jun 02, 2021 07:40 am ET
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This...
May 11, 2021 07:00 am ET
Royalty Pharma Reports First Quarter 2021 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “Royalty Pharma continued its impressive business...
May 07, 2021 09:00 am ET
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: Bank of America 2021 Healthcare Conference on Wednesday, May 12 at 9:30 a.m. EDT7th Annual Truist...
Apr 21, 2021 04:15 pm ET
Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00...
Apr 21, 2021 08:10 am ET
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, to expand MSCI’s thematic index suite with the...
Apr 15, 2021 09:00 am ET
Royalty Pharma Declares Second-Quarter 2021 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share. The dividend will be paid on June 15, 2021, to shareholders of record at the close of...
Apr 08, 2021 07:40 am ET
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180...
Apr 08, 2021 07:30 am ET
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc
Apr 01, 2021 07:30 am ET
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million and up to $50 million in additional...
Mar 30, 2021 08:00 am ET
Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive...
Feb 17, 2021 07:00 am ET
Royalty Pharma Reports Q4 2020 and Full-Year Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter of 2020 and introduced full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “Royalty Pharma achieved a number of major...
Jan 22, 2021 08:00 am ET
Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast...
Jan 19, 2021 08:30 am ET
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional...
Jan 19, 2021 08:00 am ET
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional...
Jan 08, 2021 08:00 am ET
Royalty Pharma Announces 13% Dividend Increase
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share, reflecting a 13% increase in the company’s quarterly dividend over the previous...
Jan 07, 2021 04:15 pm ET
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12
Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST. Investors, analysts, members of the media and the general public...
Dec 22, 2020 08:30 am ET
Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities
Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller University, Mount Sinai Health System and Columbia University. This amount includes donations...
Dec 21, 2020 08:12 am ET
Royalty Pharma Announces Expansion of Leadership Team
Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch, PhD will assume increased responsibilities with a new role of Chief Scientific Officer, which is in addition to his position as Co-Head of Research...
Dec 07, 2020 08:45 am ET
Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals
Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the...
Dec 07, 2020 08:40 am ET
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the...
Nov 10, 2020 05:39 pm ET
Royalty Pharma Reports Third Quarter 2020 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “Our performance in the third quarter underscored...
Nov 02, 2020 07:30 am ET
Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront...
Oct 20, 2020 04:32 pm ET
Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of...
Oct 19, 2020 09:00 am ET
Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020
Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at...
Oct 15, 2020 11:45 pm ET
Royalty Pharma Announces Pricing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration...
Oct 15, 2020 09:15 am ET
Royalty Pharma Declares Fourth-Quarter 2020 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share. The dividend will be paid on December 15, 2020, to shareholders of record at the close of...
Oct 13, 2020 04:10 pm ET
Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering. The selling shareholders are...
Sep 02, 2020 04:25 pm ET
Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes
Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due...
Sep 02, 2020 08:00 am ET
Royalty Pharma Declares Third-Quarter 2020 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2020 of $0.15 per class A share. The dividend will be paid on September 30, 2020, to shareholders of record at the close of...
Aug 25, 2020 08:00 am ET
Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes
Royalty Pharma plc announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023;$1...
Aug 19, 2020 09:00 am ET
Royalty Pharma Announces Launch of Senior Notes Offering
Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes”) in a private offering exempt from registration in accordance with Rule 144A and...
Aug 12, 2020 07:00 am ET
Royalty Pharma Reports Second Quarter 2020 Results
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2020 and introduced full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “2020 has been a landmark year for Royalty...
Aug 07, 2020 09:40 am ET
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company’s CGRP receptor antagonist program through the development of...
Aug 07, 2020 09:37 am ET
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
NEW HAVEN, Conn. and NEW YORK, Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company's CGRP receptor antagonist program through the development of zavegepant (formerly known as vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications. In exchange for these funds, Royalty Pharma will obtain a 0.4% royalty on annual worldwide net sales of Nurt
Aug 03, 2020 04:15 pm ET
Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company’s Board of Directors
Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective immediately. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc., a leading...
Jul 20, 2020 04:15 pm ET
Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12
Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast...
Jul 20, 2020 07:45 am ET
Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million. Risdiplam, to be marketed by Roche, is an...
Jun 30, 2020 10:40 am ET
New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO
VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:ADCT). The company raised $267.6 million through the sale of 14,082,475 of its common shares priced at $19.00 per share. Funds managed by New Ventures III and New Ventures Select have invested in ADCT since 2015. In just over a month, New Ventures has seen two portfolio companies complete successful public listings, the second being Royalty Pharma (NASDAQ: R
Jun 25, 2020 08:43 am ET
New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut
VIRGINIA BEACH, Va., June 25, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX). The company raised $2.18 billion through the sale of 77,681,670 of its Class A ordinary shares priced at $28.00 per share – the largest IPO of the year and the second biggest Pharma listing ever. Principals of New Ventures were day-one investors in Royalty Pharma and the New Ventures family of funds have invested in Royalty Pharma since 2006.
Jun 18, 2020 04:15 pm ET
Royalty Pharma Announces Closing of Initial Public Offering
Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission...
Jan 26, 2018 04:01 pm ET
Repros Announces Negative Opinion From the EMA for Enclomiphene
THE WOODLANDS, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.®, (Nasdaq:RPRX) ("Repros" or the "Company") today announced that, consistent with the previously disclosed guidance from the European Medicines Agency (EMA), the CHMP (Committee for Medicinal Products...
Jan 09, 2018 12:53 pm ET
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division
NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court Southern District of Texas Houston Division, case no. 4:17-cv-03918, on behalf of stockholders of Repros Therapeutics Inc. ("Repros" or the "Company") (NASDAQ: RPRX) who held Repros securities and have been harmed by Repros and its board of directors' (the "Board") for alleged violations of Sections 14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the tender offer of Comp
Jan 04, 2018 08:15 am ET
Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive La
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Athersys, Inc. (NASDAQ:ATHX), Repros Therapeutics Inc....
Dec 18, 2017 12:50 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX
NEW YORK, Dec. 18, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating Repros Therapeutics, Inc. ("Repros" or the "Company") (NasdaqCM: RPRX) relating to the sale of the Company to Allergan plc. As a result of the merger Repros shareholders are only anticipated to receive $0.67 in cash in exchange for each share of Repros.
Dec 15, 2017 04:00 pm ET
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
THE WOODLANDS, Texas, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that following an Oral Explanation, it has received feedback that a negative opinion is likely to be received in...
Dec 12, 2017 06:30 am ET
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
THE WOODLANDS, Texas, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that it has entered into a definitive agreement under which Allergan plc (“Allergan”), through a subsidiary, will acquire Repros...
Nov 13, 2017 08:45 am ET
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
THE WOODLANDS, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2017.
Jul 17, 2017 02:01 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)
NEW YORK, July 17, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repros Therapeutics Inc. ("Repros" or the "Company") (NASDAQ: RPRX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rprx.
Jul 17, 2017 01:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
NEW YORK, July 17, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repros Therapeutics, Inc. ("Repros" or the "Company") (NASDAQ:  RPRX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
May 18, 2017 08:45 am ET
Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
THE WOODLANDS, Texas, May 18, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc (Nasdaq:RPRX) (“Repros” or the “Company”), announced today that it has entered into an underwriting agreement to sell in a public offering 2,744,125 shares of the Company’s common stock (“Common Stock”) and pre-funded Series C warrants to purchase 2,245,875 shares of Common Stock, which will be offered in lieu of Common Stock to those purchasers whose purchase of Common Stock in the offering otherwise would result in the purchaser beneficially owning more than 4.99% of the Company’s outstanding common stock foll...
May 17, 2017 04:55 pm ET
Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
THE WOODLANDS, Texas, May 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) (“Repros” or the “Company”) today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Repros intends to use the net proceeds from the offering for general corporate purposes....
May 09, 2017 04:01 pm ET
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results
THE WOODLANDS, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2017....
Apr 17, 2017 09:15 am ET
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
THE WOODLANDS, Texas, April 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the issuance of a new patent, U.S. Patent number 9,616,074 (the ‘074 patent), that bolsters the Company’s intellectual property relating to Proellex® (telapristone acetate).  The ‘074 patent, which expires in 2027, relates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex®) or Ulipristal Acetate, with an Off Drug Interval (ODI) for the treatment of estrogen-dependent hyperproliferative uterine conditions, such as uterine ...
Dec 19, 2016 04:01 pm ET
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
THE WOODLANDS, Texas, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements for the development of Proellex® (telapristone acetate) for the treatment of endometriosis. The Company anticipates a meeting will be scheduled during the first half of 2017....
Dec 12, 2016 04:01 pm ET
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids
Focus on oral formulationPhase II complete THE WOODLANDS, Texas, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements for the development of Proellex® (telapristone acetate) for the treatment of symptomatic uterine fibroids. The Company anticipates a meeting will be scheduled during the first half of 2017....
Dec 06, 2016 08:01 pm ET
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
THE WOODLANDS, Texas, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting today.  The panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis.  The panel voted 16 to 5 that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provi...
Nov 08, 2016 04:00 pm ET
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
THE WOODLANDS, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2016....
Sep 26, 2016 09:15 am ET
FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
Repros Therapeutics to participate as a Sponsor -- developing a therapy specifically designed to treat secondary hypogonadism THE WOODLANDS, Texas, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today noted that it will participate as a sponsor in a forthcoming public advisory committee meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee recently announced by the Food and Drug Administration (FDA). The general function of the committee is to provide advice and recommendations to the FDA on the FDA's regulatory issues. The meeting, to be hel...
Sep 12, 2016 11:45 am ET
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
UK designated as rapporteur and France as co-rapporteurAverage time to approval 13 – 16 months THE WOODLANDS, Texas, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that, as anticipated, it has activated the process for obtaining a marketing authorization (MAA) for enclomiphene in the treatment of secondary hypogonadism in Europe....
Sep 07, 2016 04:01 pm ET
Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis
Subjects with moderate to severe endometriosis experienced relief of menstrual pain and a reduction in the use of pain medication with the use of Proellex® Proellex® subjects’ menstrual pain by BBSS decreased significantly when compared to those treated with placeboTotal pain medication use decreased 56% and non-prescription pain medication use decreased 74% in subjects treated with Proellex® THE WOODLANDS, Texas, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided the results of the first course of treatment from Repros’ ongoing study of Proellex® f...
Aug 15, 2016 04:01 pm ET
Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Six month interim assessment of testosterone (T) levels shows statistically and clinically significant increases in total T (p = 0.0017) and free T (p = 0.0020) superior to placeboEffects of diet and exercise and enclomiphene treatment are additive Diet and exercise alone increased mean total T (263.9 ng/dL to 368.2 ng/dL, p = 0.0055) and mean free T (55.6 pg/mL to 57.1 pg/mL, p = 0.0802) Enclomiphene treatment combined with diet and exercise increased mean total T (277.3 ng/dL to 780.9 ng/dL, p < 0.0001) and free T (56.3 pg/mL to 140.1 pg/mL, p = 0.0001)  Enclomiphene treatment comb...
Aug 09, 2016 09:15 am ET
Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results
THE WOODLANDS, Texas, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2016....
Jun 01, 2016 04:01 pm ET
Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
EU submission on track with anticipated registration decision expected Fall 2017 UK designated as rapporteur and France as co-rapporteur for the centralized review of the enclomiphene marketing application 3 month interim assessment of testosterone levels in obese men participating in Phase 2 diet and exercise study show statistically significant increases in testosterone in the active arms versus the placebo arm THE WOODLANDS, Texas, June 01, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it remains on track for submission of a European centralized ...
May 18, 2016 04:01 pm ET
Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004Proellex®-treated subjects reported a median 100% (mean 95%) reduction in diary reports of menstrual bleeding product usage (PBAC)Statistically significant reduction in fibroid size from baseline achieved for the combined active arms compared to increase in fibroid volume in placebo arm, p=0.0007 THE WOODLANDS, Texas, May 18, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported that oral administration of Proellex® at doses of both 6 and 12 mg achieved signific...
May 16, 2016 04:00 pm ET
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
THE WOODLANDS, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board....
May 10, 2016 09:15 am ET
Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results
THE WOODLANDS, Texas, May 10, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2016....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.